Allergan obtains FDA green light for Vuity

Allergan, an AbbVie company, has received the Food and Drug Administration’s permission for Vuity (pilocarpine HCl ophthalmic solution) 1.25%.

The product is the first and only eye drop approved by the FDA to treat presbyopia.

[Read more: FDA gives AbbVie approval for Qulipta]

The medication is now available by prescription in pharmacies nationwide.

Presbyopia, or age-related blurry near vision, can be diagnosed through a basic eye exam by an eye doctor (optometrist or ophthalmologist) and is a common and progressive eye condition that affects 128 million Americans, or nearly half of the U.S. adult population.

[Read more: AbbVie's acquisition of Allergan approved by High Court of Ireland]

"We are pleased to be able to bring this first-of-its-kind treatment to market sooner than expected for the millions of Americans with presbyopia who may benefit from it," said Jag Dosanjh, senior vice president medical therapeutics, Allergan. "This significant innovation in age-related eye health reflects our commitment to advance vision care and expands our leading portfolio of treatments for eye care providers and their patients."